Abstract

A single mutation (C73R) in the enzyme uroporphyrinogen III synthase (UROIIIS) is responsible for more than one-third of all of the reported cases of the rare autosomal disease congenital erythropoietic porphyria (CEP). CEP patients carrying this hotspot mutation develop a severe phenotype of the disease, including reduced life expectancy. Here, we have investigated the molecular basis for the functional deficit in the mutant enzyme both in vitro and in cellular systems. We show that a Cys in position 73 is not essential for the catalytic activity of the enzyme but its mutation to Arg speeds up the process of irreversible unfolding and aggregation. In the mammalian cell milieu, the mutant protein levels decrease to below the detection limit, whereas wild type UROIIIS can be detected easily. The disparate response is not produced by differences at the level of transcription, and the results with cultured cells and in vitro are consistent with a model where the protein becomes very unstable upon mutation and triggers a degradation mechanism via the proteasome. Mutant protein levels can be restored upon cell treatment with the proteasome inhibitor MG132. The intracellularly recovered C73R-UROIIIS protein shows enzymatic activity, paving the way for a new line of therapeutic intervention in CEP patients.

Highlights

  • In the bone marrow, teeth, stool, and urine as well as skin photosensitivity [2]

  • Wild type uroporphyrinogen III synthase (UROIIIS) had a half-life of 61 h as compared with 15 min observed with C73R-UROIIIS, which was in very good agreement with the time dependence of the catalytic activity of the enzyme

  • Congenital erythropoietic porphyria is a rare disease produced by the loss of activity in the enzyme uroporphyrinogen III synthase

Read more

Summary

Introduction

In the bone marrow, teeth, stool, and urine as well as skin photosensitivity [2]. CEP patients suffer from hemolytic anemia and splenomegaly, and they have red-colored urine. The same stable cell line from each of the different WT and C73R versions of the UROIIIS protein was selected to perform this study.

Results
Conclusion
Full Text
Published version (Free)

Talk to us

Join us for a 30 min session where you can share your feedback and ask us any queries you have

Schedule a call